

Design and Characterization of a Heterodimeric Coiled Coil that Forms Exclusively with an Antiparallel Relative Helix Orientation

Diana L. McClain, Howard L. Woods, and Martha G. Oakley*

Department of Chemistry, Indiana University
800 East Kirkwood Avenue, Bloomington, Indiana 47405-7102

Received November 28, 2000

Coiled coils are formed by two or more α -helices that align in a parallel or an antiparallel relative orientation. In spite of the growing biological importance of antiparallel coiled coils, the study of this class of molecules has been hampered by the lack of a suitable model system. We report here the successful design of a well-behaved antiparallel coiled-coil heterodimer. The antiparallel helix orientation preference for this model coiled coil is similar in magnitude to the parallel preference of naturally occurring leucine zipper peptides, providing a useful tool for controlling the relative orientation of heterologous protein subdomains.

Coiled coils are found both as the dominant motif in fibrous proteins and as oligomerization domains in a variety of globular proteins.¹ The α -helices of naturally occurring coiled coils have generally been assumed to be parallel. However, a growing number of proteins have been shown to contain antiparallel coiled-coil domains.^{2,3}

The discovery that the basic region–leucine zipper class of transcription factors⁴ contains short coiled-coil dimerization domains⁵ has provided an invaluable, tractable model system for parallel coiled-coil formation. These parallel coiled coils also have been used to assemble complexes of heterologous domains for structural and functional studies.⁶ In contrast, no naturally occurring coiled coil has proven suitable as an antiparallel counterpart to the leucine zipper peptides.

It has been shown recently that a single buried polar interaction can confer an antiparallel preference of approximately 2.3 kcal/mol to the model coiled coil Acid-a1–Base-a1.⁷ A similar coiled coil has been used to reassemble the N- and C-terminal domains of the green fluorescent protein into a functional complex.⁸

* To whom correspondence should be addressed.

- (1) Lupas, A. *Trends Biochem. Sci.* **1996**, *21*, 375–382.
 (2) Cusack, S.; Berthet-Colominas, C.; Härtlein, M.; Nassar, N.; Leberman, R. *Nature* **1990**, *347*, 249–255.
 (3) (a) Biou, V.; Yaremchuk, A.; Tukalo, M.; Cusack, S. *Science* **1994**, *263*, 1404–1410. (b) Stebbins, C. E.; Borukhov, S.; Orlova, M.; Polyakov, A.; Goldfarb, A.; Darst, S. A. *Nature* **1995**, *373*, 636–640. (c) Uhlin, U.; Cox, G. B.; Guss, J. M. *Structure* **1997**, *5*, 1219–1230. (d) Bussiere, D. E.; Bastia, D.; White, S. W. *Cell* **1995**, *80*, 651–660. (e) Soisson, S. M.; MacDougall-Shackleton, B.; Schleif, R.; Wolberger, C. *Science* **1997**, *276*, 421–425. (f) Zuccola, H. J.; Rozzelle, J. E.; Lemon, S. M.; Erickson, B. W.; Hogle, J. M. *Structure* **1998**, *6*, 821–830. (g) Melby, T. E.; Ciampaglio, C. N.; Briscoe, G.; Erickson, H. P. *J. Cell Biol.* **1998**, *142*, 1595–1604. (h) Hopfner, K.; Karcher, A.; Shin, D. S.; Craig, L.; Arthur, L. M.; Carney, J. P.; Tainer, J. A. *Cell* **2000**, *101*, 789–800.
 (4) Landschulz, W. H.; Johnson, P. F.; McKnight, S. L. *Science* **1988**, *240*, 1759–1764.
 (5) O'Shea, E. K.; Rutkowski, R.; Kim, P. S. *Science* **1989**, *243*, 538–542.
 (6) (a) Wilcox, B. E.; Gao, G. F.; Wyer, J. R.; O'Callaghan, C. A.; Boulter, J. M.; Jones, E. Y.; Van Der Merwe, P. A.; Bell, J. I.; Jakobsen, B. K. *Protein Sci.* **1999**, *8*, 2418–2423. (b) Weissenhorn, W.; Calder, L. J.; Wharton, S. A.; Skehel, J. J.; Wiley, D. C. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 6032–6036. (c) Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. *Nature* **1997**, *387*, 426–430. (d) Herrmann, H.; Strelkov, S. V.; Feja, B.; Rogers, K. R.; Brettel, M.; Lustig, A.; Häner, M.; Parry, D. A. D.; Steinert, P. M.; Burkhard, P.; Aebi, U. *J. Mol. Biol.* **2000**, *298*, 817–832. (e) Greenfield, N. J.; Montelione, G. T.; Farid, R. S.; Hitchcock-DeGregori, S. E. *Biochemistry* **1998**, *37*, 7834–7843.
 (7) Oakley, M. G.; Kim, P. S. *Biochemistry* **1998**, *37*, 12603–12610.
 (8) Ghosh, I.; Hamilton, A. D.; Regan, L. *J. Am. Chem. Soc.* **2000**, *122*, 5658–5659.

However, the modest antiparallel preference of this coiled coil is likely to preclude its use in applications for which the heterologous domains do not influence helix orientation preference.

Coiled-coil sequences are characterized by a heptad repeat of amino acid residues, denoted **a–g**.⁹ The residues at positions **a** and **d** are predominantly apolar, with charged residues occurring frequently at the **e** and **g** positions.⁹ Residues at these four positions participate in interhelical hydrophobic and Coulombic interactions.¹⁰ The relative positions of residues expected to engage in Coulombic interactions are known from the three-dimensional structures of coiled coils.^{2,10} In parallel coiled coils, residues at the **e** position can interact with **g'** residues on the opposite strand. In antiparallel coiled coils, **g** residues interact with **g'** residues, while **e** residues can interact with **e'** residues. Potentially attractive and repulsive Coulombic interactions between residues at these positions have been shown to influence partner strand specificity.¹¹ Similarly, such interactions have been reported to affect orientation preference in disulfide-linked model coiled coils.¹² However, the extent to which a single or pair of differential interactions can contribute to helix orientation preference is unknown.

Because Acid-a1 contains only Glu residues and Base-a1 only Lys residues at both the **e** and **g** positions,⁷ only potentially attractive interhelical Coulombic interactions are expected in either orientation. We substituted a single residue at a **g** position in each peptide such that all potentially attractive interactions are expected in the antiparallel orientation. In contrast, two potentially repulsive Coulombic interactions are expected in the parallel orientation. The buried polar interaction between interior Asn residues can occur only in the antiparallel orientation (Figure 1).

An equimolar mixture of the resulting peptides, Acid-Kg and Base-Eg, forms a stable heterodimer, as demonstrated by CD (Figure 2A) and equilibrium sedimentation studies (data not shown). To probe the relative helix orientation in this heterodimer, three additional peptides with flexible Cys-containing tripeptides at the N- or C-terminus were synthesized: Acid-KgN, Base-EgN, and Base-EgC. CD studies show that both the antiparallel, covalently linked heterodimer, Acid-KgN–Base-EgC, and its parallel counterpart, Acid-KgN–Base-EgN, are highly helical at 25 °C. Nonetheless, the antiparallel heterodimer is substantially more stable to thermal denaturation than its parallel counterpart (Figure 2B), strongly suggesting that the antiparallel orientation is preferred.

The preference for an antiparallel helix orientation under equilibrium conditions was monitored with use of a thiol–disulfide exchange assay^{7,13} (Figure 3). Acid-KgN–Base-EgN (10 μ M) and Base-EgC (11 μ M) were mixed (PBS buffer, pH 7) and allowed to equilibrate (Figure 3C). The observed equilibrium

- (9) (a) McLachlan, A. D.; Stewart, M. J. *Mol. Biol.* **1975**, *98*, 293–304. (b) Hodges, R. S.; Sodek, J.; Smillie, L. B.; Jurasek, L. *Cold Spring Harbor Symp. Quantum Biol.* **1972**, *37*, 299–310. (c) Parry, D. A. D. *Biosci. Rep.* **1982**, *2*, 1017–1024.
 (10) O'Shea, E. K.; Klemm, J. D.; Kim, P. S.; Alber, T. *Science* **1991**, *254*, 539–544.
 (11) (a) O'Shea, E. K.; Rutkowski, R.; Kim, P. S. *Cell* **1992**, *68*, 699–708. (b) O'Shea, E. K.; Lumb, K. J.; Kim, P. S. *Curr. Biol.* **1993**, *3*, 658–667. (c) Sharma, V. A.; Logan, J.; King, D. S.; White, R.; Alber, T. *Curr. Biol.* **1998**, *8*, 823–830. (d) Nautiyal, S.; Woolfson, D. N.; King, D. S.; Alber, T. *Biochemistry* **1995**, *34*, 11645–11651. (e) Lavigne, P.; Kondejewski, L. H.; Houston, M. E., Jr.; Sönnichsen, F. D.; Lix, B.; Sykes, B. D.; Hodges, R. S.; Kay, C. M. *J. Mol. Biol.* **1995**, *254*, 505–520. (f) Vinson, C. R.; Hai, T.; Boyd, S. M. *Genes Dev.* **1993**, *7*, 1047–1058. (g) Nicklin, M. J. H.; Casari, G. *Oncogene* **1991**, *6*, 173–179. (h) Schuermann, M.; Hunter, J. B.; Hennig, G.; Müller, R. *Nucleic Acids Res.* **1991**, *19*, 739–746.
 (12) (a) Monera, O. D.; Zhou, N. E.; Kay, C. M.; Hodges, R. S. *J. Biol. Chem.* **1993**, *268*, 19218–19227. (b) Monera, O. D.; Kay, C. M.; Hodges, R. S. *Biochemistry* **1994**, *33*, 3862–3871.
 (13) (a) Harbury, P. B.; Zhang, T.; Kim, P. S.; Alber, T. *Science* **1993**, *262*, 1401–1407. (b) Harbury, P. B.; Kim, P. S.; Alber, T. *Nature* **1994**, *371*, 80–83. (c) Lumb, K. J.; Kim, P. S. *Biochemistry* **1995**, *34*, 8642–8648.

